Press Release

09/28/18
Radius Health to Present at the Leerink Partners Oncology Roundtable Series

WALTHAM, Mass., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO and Charles Morris, Chief Medical Officer of the Company will present a corporate update at the Leerink Partners Oncology Roundtable Series on Wednesday, October 3, 2018. 

Information on the presentation is as follows:

Event:                  Leerink Partners Roundtable Series: Oncology
Date:                    Wednesday, October 3, 2018
Time:                   11:00 a.m. EST
Location:              Kennedy II, Lotte New York Palace, 455 Madison Avenue New York, NY

A live webcast of the presentation will be available by visiting the Investors section of Radius' website at http://ir.radiuspharm.com/events.cfm. A replay of the webcast will be archived on Radius' website for 90 days following the presentation.

About Radius Health

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com

Investor Relations Contact:

Elhan Webb, CFA
Email: ewebb@radiuspharm.com
Phone: 617-551-4011

radius logo.jpg

Source: Radius Health Inc.